Abstract Ovarian cancer (OvCa) is the gynaecological disorder with the poorest prognosis due to the fast development of chemoresistance. We sought to connect chemoresistance and cancer cell‐derived extracellular vesicles (EV). The mechanisms of how chemoresistance is sustained by EV remained elusive. One potentially contributing factor is A Disintegrin and Metalloprotease 17 (ADAM17)—itself being able to promote chemoresistance and inducing tumour cell proliferation and survival via the Epidermal Growth Factor Receptor (EGFR) pathway by shedding several of its ligands including Amphiregulin (AREG). We now demonstrate that upon chemotherapeutic treatment, proteolytically active ADAM17 is released in association with EV from OvCa cells. In terms of function, we show that patient‐derived EV induce AREG shedding and restore chemoresistance in ADAM17‐deficient cells. Confirming that ADAM17‐containing EV transmit chemoresistance in OvCa, we propose that ADAM17 levels (also on EV) might serve as an indicator for tumour progression and the chemosensitivity status of a given patient.
There are few, but worrisome, data available on fingertip
radiation exposure of medical personnel during
radiosynovectomy (RSV). To reduce radiation exposure, we
performed a dedicated application procedure. This report
summarizes the acquired skin equivalent dose [Hp(0.07)] of
the personnel involved in the preparation and administration
of the three RSV !-emitters 90Y, 186Re and 169Er. Over a
period of 3 years, 547 joints in 368 patients were treated
with 52 421MBq of the aforementioned three radionuclides.
The Hp(0.07) was recorded with thermoluminescence
dosimeters worn on the dominant index fingertip and was
analysed monthly. Eight staff members were exposed to an
Hp(0.07) of 492 mSv. The cumulative dose was less than 10
μSv/MBq. The dose per person was 1.1 μSv/MBq in
physicians and up to 4.5 μSv/MBq in technicians. The
accumulated personal Hp(0.07) during RSV was far below
the regulatory limit and published data.
There are few, but worrisome, data available on fingertip radiation exposure of medical personnel during radiosynovectomy (RSV). To reduce radiation exposure, we performed a dedicated application procedure. This report summarizes the acquired skin equivalent dose [Hp(0.07)] of the personnel involved in the preparation and administration of the three RSV β-emitters 90Y, 186Re and 169Er. Over a period of 3 years, 547 joints in 368 patients were treated with 52 421 MBq of the aforementioned three radionuclides. The Hp(0.07) was recorded with thermoluminescence dosimeters worn on the dominant index fingertip and was analysed monthly. Eight staff members were exposed to an Hp(0.07) of 492 mSv. The cumulative dose was less than 10 μSv/MBq. The dose per person was 1.1 μSv/MBq in physicians and up to 4.5 μSv/MBq in technicians. The accumulated personal Hp(0.07) during RSV was far below the regulatory limit and published data.
